Peptides for Menopause: An Evidence Table for Every Compound Marketed to Women Over 40
Last updated: October 27, 2026 · 13 min read · By the Grey Peptides Editorial Board
- The best-known peptide marketed to this group excludes it. Bremelanotide's own label says it is not indicated for hypoactive sexual desire disorder in postmenopausal women.
- The International Menopause Society's 2025 recommendations call hormone therapy the most effective treatment for hot flushes and night sweats, and two non-hormonal drugs are now approved in the US for them, neither of which is a peptide.
- The peptides with real evidence in this population are approved GLP-1 drugs for weight, and 5 g a day of collagen peptides in a 12-month bone-density trial in postmenopausal women.
- For BPC-157, CJC-1295, ipamorelin, sermorelin, epitalon, MOTS-c and thymosin alpha-1, a PubMed search found no study in menopausal women at all. NAD+ itself has none either, though its precursors do.
- Oxytocin gel for vaginal atrophy has been tested: a 2023 meta-analysis found less clinically assessed atrophy than with placebo, but no significant difference on dyspareunia, vaginal pH, histology or the maturation index.
What the specialists recommend first
Before any peptide, the thing worth knowing is what the people who treat menopause for a living recommend. The International Menopause Society's 2025 recommendations, built on a systematic review, say that menopausal hormone therapy is the most effective treatment for vasomotor symptoms — hot flushes and night sweats — and should be offered to women with bothersome symptoms who have no significant contraindication, and that for this use it is typically recommended to women younger than 60 or within 10 years of menopause after a full evaluation of benefits and risks. For the genitourinary syndrome of menopause they recommend offering vaginal estrogen therapy.1
For women who cannot or prefer not to take it, the same recommendations name neurokinin-targeted drugs as the preferred non-hormonal option, with effectiveness slightly lower than hormone therapy.1 Two are approved in the United States specifically for moderate to severe vasomotor symptoms due to menopause, and neither is a peptide. Fezolinetant, a neurokinin 3 receptor antagonist, was approved in May 2023; its label carries a boxed warning for liver injury and requires liver tests before starting and during treatment.2 Elinzanetant, which blocks both neurokinin 1 and 3 receptors, was approved in the US in October 2025, after a first approval in the UK in July 2025; its label also requires liver tests before starting.3 4
That is the comparison every peptide below is implicitly competing with: a first-line treatment and two approved alternatives, each backed by randomised trials.1 We found no trial comparing any compound in the table with any of them.5
The label line that excludes this entire group
PT-141 is the research name of bremelanotide, and bremelanotide is approved: Vyleesi, approved in June 2019, for premenopausal women with acquired, generalised hypoactive sexual desire disorder.6
Its label also contains a Limitations of Use section, and that section says, in the label's own words, that it is not indicated for the treatment of HSDD in postmenopausal women or in men, and not indicated to enhance sexual performance.6 The two phase 3 trials enrolled premenopausal women, mean age 39, and were funded by its developers, Palatin Technologies and AMAG Pharmaceuticals.7 Using it for low desire after menopause is not an off-label nuance; it is use in a population the label specifically carves out.
There is a second thing worth knowing even within the approved population. The two phase 3 trials showed statistically significant improvements in desire and related distress, and independent re-analyses published since have argued the effects were modest, that most protocol-listed outcomes went unreported while unlisted ones were published, and that discontinuation for adverse events was far higher on the drug.8 9 The original authors, two of them from Palatin, have replied.10 Our PT-141 entry carries both sides.
The evidence table
Compounds discussed for women over 40, what has been measured in this population, and the evidence grade from our encyclopedia. Grades reflect all human evidence for the compound, not only its menopause data. For each one we searched PubMed for studies in menopausal women on October 27, 2026.5
| Compound | Asked about for | Evidence in menopausal or postmenopausal women | Grade |
|---|---|---|---|
| Semaglutide, tirzepatide | Midlife weight gain, central fat | Real but mostly indirect. A 2026 scoping review found weight loss and reduced central adiposity in this group, with only limited studies on vasomotor symptoms.11 A 2026 Spanish Menopause Society position statement says semaglutide has the most direct menopause-specific evidence of any incretin drug, and that it remains limited and largely observational.12 | High |
| Collagen peptides | Skin, joints, bone | A randomised trial in this population: 131 postmenopausal women with low bone density randomised to 5 g a day or placebo for 12 months, with increased bone mineral density and a rise in the bone formation marker P1NP; a co-author was from a collagen research institute.13 | Medium |
| PT-141 (bremelanotide) | Low desire | Approved, and its label states it is not indicated for HSDD in postmenopausal women.6 Trials enrolled premenopausal women.7 | High |
| Oxytocin gel | Vaginal dryness, atrophy | Tested, with mixed results: a 2023 systematic review and meta-analysis of seven trials (631 women) found less clinically assessed vaginal atrophy with oxytocin than with placebo gel, but no significant difference in dyspareunia, vaginal pH, histological atrophy or the maturation index; the authors concluded the findings did not support it as an alternative to estrogen.14 | High |
| GHK-Cu | Skin ageing | No menopause-specific study found.5 A 2026 review calls its clinical evidence sparse; a 13-person study after CO2 laser treatment was negative on objective endpoints.15 | Medium |
| CJC-1295, ipamorelin, sermorelin | Body composition, sleep, "menopause belly" | None found.5 CJC-1295 raised growth hormone and IGF-1 in healthy adults aged 21 to 61 in two small randomised trials,16 but no study has tested any outcome in menopausal women. | Medium |
| BPC-157 | Joint and gut complaints | None found.5 Its published human record is a single clinic's telephone survey of 16 patients given knee injections17 and a two-person intravenous safety pilot,18 in neither case a menopause population. | Low |
| DSIP | Menopausal insomnia | A 1992 double-blind trial in 16 people with chronic insomnia found weak effects and concluded it was not likely to be of major benefit.19 No menopause study found.5 | Medium |
| MOTS-c, NAD+ | Energy, metabolic "reset" | MOTS-c: no human study in this population; it prevented weight gain and insulin resistance in ovariectomised mice.20 NAD+: a 2026 systematic review found no outcomes trial of intravenous or intramuscular NAD+ itself for ageing or wellness in anyone.21 Its precursors have been tested here: oral NMN for 10 weeks raised muscle insulin sensitivity in 25 postmenopausal women with prediabetes in a randomised trial,22 and a 7-day open-label pilot of nicotinamide riboside with pterostilbene in 40 women, written by employees of the supplement's maker, reported fewer hot flushes with no control group.23 | Low |
| Thymosin alpha-1 | Immune support | None found in this population.5 | High |
Where the GLP-1 evidence actually stands
This is the one area where a peptide drug has genuine evidence for a menopause-related problem.
What is established: GLP-1 receptor agonists produce weight loss and reduce central adiposity in menopausal and postmenopausal women, as a 2026 scoping review of this population found. The same review notes that improvements in vasomotor symptoms and cardiovascular markers were reported in only a limited number of studies, and calls for larger studies in menopausal women.11
A 2026 position statement coordinated by the Spanish Menopause Society's young investigators group with senior society experts, developed from a literature search through April 2026, is more specific. It concludes that semaglutide provides the largest body of direct menopause-specific evidence among the incretin drugs, and that this evidence remains limited and largely observational. It also addresses the reported association between taking hormone therapy alongside semaglutide and greater weight loss: the statement calls that association hypothesis-generating and says explicitly that it should not justify starting hormone therapy solely to augment weight loss.12
The one trial that was actually done in this population
If you want a peptide with randomised evidence in postmenopausal women specifically, it is a collagen supplement. A 12-month randomised, double-blind, placebo-controlled trial gave 131 postmenopausal women with primary, age-related reduction in bone mineral density (mean spine T-score -2.4) either 5 g a day of specific collagen peptides or placebo; 102 finished, and all were analysed. Bone mineral density at the spine and femoral neck increased in the collagen group compared with placebo, and the bone formation marker P1NP rose in that group while the resorption marker CTX-1 rose in the control group.13
Two caveats belong with it. The open-label four-year follow-up covered 31 women, all taking the peptides, with no control group, so it supports rather than confirms.24 And a co-author of the trial, and two of the three authors of the follow-up, were from the Collagen Research Institute in Kiel,13 24 which does not make the result false but does narrow what it supports: a specific preparation at a specific dose, not collagen in general. Our collagen peptides review covers the rest.
Note also what the trial is not. It measured bone density, not fractures, over one year.13 Bisphosphonates, by contrast, have proven efficacy in preventing osteoporosis-related fractures.1
What it means when a compound has no row
Most of the table says the same thing: no trial in this population. That deserves a sentence, because "no evidence" gets read two ways and only one of them is right.
It does not mean a compound has been shown not to work in menopausal women. It means no published study has looked.5 For BPC-157 the human evidence in any population is two small reports,17 18 so the absence of menopause data is not surprising. A claim that one of these compounds treats perimenopausal symptoms rests on mechanism or animal work, not on a study in women going through it.
That matters more in midlife than it might elsewhere. The International Menopause Society's recommendations cover weight gain and body-composition change, sleep disturbance, mood, skin and connective tissue, and low desire alongside hot flushes,1 the same ground the table's compounds are asked about for. A compound offered for sleep, energy, body composition and skin can appear to address four menopause symptoms at once without a single study in anyone going through it.
The question a weight drug raises specifically in this group
The Spanish Menopause Society statement organises its guidance around body composition, cardiometabolic risk, musculoskeletal health, monitoring and hormone therapy rather than weight alone, and asks that incretin therapy in menopause be considered alongside visceral fat, skeletal muscle health, fracture risk, resistance exercise, adequate protein intake and structured monitoring.12 Menopause is associated with significant bone loss, and the International Menopause Society recommends resistance and weight-bearing exercise for all postmenopausal women.1
So the question that matters in this population is not only how much weight came off but what came off with it, and what is being done about it. That is a conversation about resistance training, protein intake and bone monitoring alongside the drug, not an argument against the drug.12
It is worth noting what the collagen trial in this group did and did not show here as well. It measured bone mineral density over 12 months, not fractures.13 Density is a surrogate. Bisphosphonates have fracture-prevention evidence behind them;1 nothing on this page does.
Where these peptides come from, and why that matters here
Most of the compounds in the table are not approved drugs. Outside approved products there are two routes, and the difference between them is worth understanding before a first appointment.
The first is a clinic that prescribes a compounded preparation. What a 503A pharmacy may compound from a bulk drug substance depends on FDA's lists and its categories for nominated substances.25 FDA's compounding advisory committee reviewed seven peptides, among them BPC-157, epitalon and MOTS-c, at its July 23-24, 2026 meeting.26 Our regulatory tracker follows each compound's status, dated at the source, including what FDA has and has not decided since.
The second is a research-chemical vial bought online, made without pharmacy oversight. Our verification guide and COA decoder set out what a seller's certificate does and does not establish, including whether it covers sterility, which matters for anything injected.
The practical point for a reader here is that the question "does this peptide work for menopause" and the question "is what I would be injecting what the label says" are separate, and both have to be answered. For most compounds in the table the first answer is "untested in this population", which makes the second one moot.
Questions worth asking a clinic
If a clinic recommends a peptide for menopausal symptoms, these are checkable rather than argumentative.
- Which trial was run in women like me? Not which mechanism, which trial, and in what population. For most of the compounds above, the honest answer is none.
- Is this approved, and for what? Approved for something else is not approved for this. Tesamorelin is approved to reduce excess abdominal fat in adults with HIV and lipodystrophy, and its label says it is not indicated for weight-loss management.27
- Why this before hormone therapy, or before the two approved non-hormonal drugs? If there is a reason — a contraindication, a preference, a prior adverse reaction — it should be stated and recorded.
- What would tell us it is not working, and when do we stop? A treatment with no stopping rule is a subscription.
- Who tested this vial? For compounded or research-sourced peptides, a purity certificate from the seller is not an independent test, and a purity result is not a sterility result. Our COA decoder covers what a certificate does and does not establish.
The short version
Hormone therapy is the most effective treatment for the symptoms most women come in with, and two non-hormonal drugs are now approved for hot flushes. Among peptides, GLP-1 drugs have real evidence for midlife weight and central fat, with menopause-specific data that experts describe as limited and largely observational. Collagen peptides have one good 12-month bone trial in postmenopausal women. Bremelanotide is approved, and its label excludes postmenopausal women from its indication.
Of the other peptides in the table, none has a published study in menopausal women, and oxytocin gel's trials were mixed. That is not a reason to assume harm; it is a reason not to pay for certainty nobody has. Each compound's own entry in our encyclopedia sets out what has been measured, in whom, and what its regulatory and sport status is, dated at the source.
Frequently asked questions
Do peptides replace HRT?
No. The International Menopause Society's 2025 recommendations call hormone therapy the most effective treatment for hot flushes and night sweats and recommend vaginal estrogen for the genitourinary syndrome of menopause, and no peptide is approved for those symptoms. GLP-1 drugs can help with weight and central fat alongside hormone therapy, and PT-141 is labelled only for premenopausal women.
What is the best peptide for menopause?
No peptide is approved for menopausal symptoms. The ones with real evidence in this population are GLP-1 drugs for weight and central fat, where menopause-specific data are limited and largely observational, and collagen peptides, which have one 12-month randomised bone-density trial in 131 postmenopausal women at 5 g a day.
Is PT-141 safe for postmenopausal women?
Its label answers a narrower question first: bremelanotide is not indicated for hypoactive sexual desire disorder in postmenopausal women. The trials enrolled premenopausal women, so there is no approved indication and no trial population that matches.
Do peptides help with menopause weight gain?
GLP-1 receptor agonists do produce weight loss and reduced central adiposity in menopausal and postmenopausal women. Growth hormone secretagogues marketed for 'menopause belly' — CJC-1295, ipamorelin, sermorelin — have no trial in this population at all.
Does taking HRT with a GLP-1 drug improve weight loss?
A 2026 Spanish Menopause Society position statement describes that association as hypothesis-generating and says it should not justify starting hormone therapy solely to augment weight loss.
What about oxytocin gel for vaginal dryness?
It has been tested. A 2023 systematic review and meta-analysis found less clinically assessed vaginal atrophy than with placebo gel, but no significant difference in dyspareunia, vaginal pH or histological evaluation of atrophy. The International Menopause Society recommends offering vaginal estrogen for the genitourinary syndrome of menopause.
Are there non-hormonal options that are actually approved?
Yes, two, and neither is a peptide. Fezolinetant was approved in May 2023 and carries a boxed warning for liver injury requiring liver tests before and during treatment. Elinzanetant was approved in October 2025, and its label also requires liver tests before starting. Both are for moderate to severe vasomotor symptoms due to menopause.
Related on Grey Peptides
- Peptides and women's health: approved, studied, thin evidence
- PT-141 (bremelanotide)
- Collagen peptides: the trial evidence
- Semaglutide
- Peptide encyclopedia
Sources
- Panay, N. et al. (2025). International Menopause Society (IMS) recommendations and key messages on women's midlife health and menopause. Climacteric, 28(6), 634-656. Full text read October 27, 2026. PMID: 41433054
- Veozah (fezolinetant) prescribing information, Indications and Usage and boxed warning, risks of hepatotoxicity (DailyMed SPL version 8, effective February 26, 2026; read October 1 and October 27, 2026, still current). Approved as NDA 216578 on May 12, 2023 (Drugs@FDA). DailyMed
- Lynkuet (elinzanetant) prescribing information, Indications and Usage and section 2 baseline hepatic tests (DailyMed SPL version 10, effective June 16, 2026; read October 1 and October 27, 2026, still current). Approved as NDA 219469 on October 24, 2025 (Drugs@FDA). DailyMed
- Lee, A. (2025). Elinzanetant: First Approval. Drugs, 86(1), 121-125. PMID: 41222830
- PubMed search, October 27, 2026: (BPC-157 OR CJC-1295 OR ipamorelin OR sermorelin OR epitalon OR epithalon OR MOTS-c OR thymosin alpha 1 OR GHK-Cu OR copper tripeptide OR delta sleep-inducing peptide) AND (menopause OR menopausal OR postmenopausal OR perimenopausal): 5 records, none a study giving any of them to menopausal women (one study of MOTS-c in ovariectomised mice; two 1992 reviews and a 1985 measurement study of thymic hormones; one MOTS-c review). A separate search for NAD+, nicotinamide riboside or NMN with menopause terms and trial or randomised: 16 records, two of them trials in this population (cited). PubMed
- Vyleesi (bremelanotide) prescribing information, Indications and Usage including Limitations of Use (DailyMed SPL version 1, effective November 13, 2025; read October 1 and October 27, 2026, still current). Approved as NDA 210557 on June 21, 2019 (Drugs@FDA). DailyMed
- Kingsberg, S. A. et al. (2019). Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics and Gynecology, 134(5), 899-908. PMID: 31599840
- Spielmans, G. I. (2021). Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder' in Women. Journal of Sex Research, 58(9), 1085-1105. PMID: 33678061
- Spielmans, G. I. & Ellefson, E. M. (2024). Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder. Journal of Sex Research, 61(4), 540-561. PMID: 36809187
- Kingsberg, S. A. et al. (2021). Failure of a Meta-analysis: A Commentary on Glen Spielmans's 'Re-Analyzing Phase III Bremelanotide Trials'. Journal of Sex Research, 58(9), 1106-1107. Two authors from Palatin Technologies. PMID: 33835907
- Graczyk, N. A. et al. (2026). Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review. Cureus, 18(1), e101693. PMID: 41704988
- Sánchez-Prieto, M. et al. (2026). Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas, 213, 109101. PMID: 42664617
- König, D. et al. (2018). Specific Collagen Peptides Improve Bone Mineral Density and Bone Markers in Postmenopausal Women - A Randomized Controlled Study. Nutrients, 10(1), 97. Co-author from the Collagen Research Institute, Kiel. PMID: 29337906
- Farahat, R. A. et al. (2023). The efficacy of oxytocin gel in postmenopausal women with vaginal atrophy: an updated systematic review and meta-analysis. BMC Women's Health, 23(1), 494. PMID: 37716966
- Mateescu, D.-M. et al. (2026). GHK-Cu as a Bioactive Metallopeptide and Drug-Delivery Cargo: Coordination Chemistry, Formulation Science, Therapeutic Evidence, and a Translational Roadmap. Pharmaceutics, 18(9). PMID: 42797253
- Teichman, S. L. et al. (2006). Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab, 91(3), 799-805. PMID: 16352683
- Lee, E. & Padgett, B. (2021). Intra-articular injection of BPC 157 for multiple types of knee pain. Alternative Therapies in Health and Medicine, 27(4), 8-13. PMID: 34324435
- Lee, E. & Burgess, K. (2025). Safety of intravenous infusion of BPC157 in humans: a pilot study. Alternative Therapies in Health and Medicine, 31(5), 20-24. PMID: 40131143
- Bes, F. et al. (1992). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology, 26(4), 193-197. PMID: 1299794
- Lu, H. et al. (2019). MOTS-c peptide regulates adipose homeostasis to prevent ovariectomy-induced metabolic dysfunction. Journal of Molecular Medicine, 97(4), 473-485. PMID: 30725119
- Gallagher, C. & Emmanuel, O. O. (2026). NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence. Ageing Research Reviews, 116, 103057. First author's affiliation is an aesthetics-business management company. PMID: 41655607
- Yoshino, M. et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224-1229. PMID: 33888596
- Holmes, H. E. et al. (2026). Nicotinamide riboside and pterostilbene reduces frequency and severity of undesirable symptoms of the menopause transition: an open-label, pilot clinical trial. Frontiers in Aging, 7, 1773667. Three authors employed by the supplement's maker. PMID: 42211736
- Zdzieblik, D. et al. (2021). Specific Bioactive Collagen Peptides in Osteopenia and Osteoporosis: Long-Term Observation in Postmenopausal Women. Journal of Bone Metabolism, 28(3), 207-213. Two authors from the Collagen Research Institute, Kiel. PMID: 34520654
- US FDA. Bulk drug substances nominated for use in compounding under section 503A: categories list (updated May 14, 2026); read October 27, 2026. FDA
- US FDA. July 23-24, 2026 meeting of the Pharmacy Compounding Advisory Committee: briefing documents for BPC-157, emideltide, epitalon, KPV, MOTS-c, semax and TB-500 (content current as of August 6, 2026); read October 27, 2026. FDA
- EGRIFTA WR (tesamorelin) prescribing information, Indications and Usage including Limitations of Use (DailyMed SPL version 2, effective July 29, 2026; read October 27, 2026). FDA
This article is for education. It is not medical advice and it is not a recommendation to take or avoid any treatment. Decisions about menopause care, including hormone therapy, belong with a clinician who knows your history.
New guides and rule changes, by email
One short email when a peptide's legal status moves — an FDA or PCAC decision, a WADA list change, an enforcement action — plus new guides and tools. At most one a week, and none when nothing changes. The newsletter has not started sending yet: your first email will be its first issue.
We keep your email address and the page you signed up from, nothing else. How it works · Privacy · RSS instead